Molecular Changes Associated With Teprotumumab Treatment in Thyroid Eye Disease @checkrare
Molecular Changes Associated With Teprotumumab Treatment in Thyroid Eye Disease  @checkrare
Uploaded November 2026 | Updated November 2026, 4 days ago
Sarah Cheng, MD, PhD, a clinical oculoplastic fellow at the University of California, San Diego, discusses findings from an exploratory study examining the biological changes in orbital tissue associated with Tepezza (teprotumumab-trbw) treatment. The findings were presented at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, Louisiana.
Molecular Changes Associated With Teprotumumab Treatment in Thyroid Eye DiseaseMiv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia GravisNarcolepsy Awareness MonthFirst-Line Therapy Approved for Rare Lung Cancer  Safety and Efficacy of Kygevvi in Thymidine Kinase 2 DeficiencyPredicting Treatment Response Outcomes With Proteomic and Machine Learning Analyses in MGDiagnostic Delay in Endocrine DisordersNeuroblastoma: The Children’s Oncology GroupGetting a Rare Disease Drug Approved Is Only Half the Battle | The CheckRare Brief Ep 4Gambling on Clinical TrialsAugust Is SMA Awareness MonthA Patient’s Journey With Essential Thrombocythemia and Polycythemia Vera
CheckRare |

Molecular Changes Associated With Teprotumumab Treatment in Thyroid Eye Disease

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER